Mixed Dyslipidemia - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 69 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Mixed Dyslipidemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Mixed Dyslipidemia - Pipeline Review, H1 2016', provides an overview of the Mixed Dyslipidemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Mixed Dyslipidemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Mixed Dyslipidemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Mixed Dyslipidemia
- The report reviews pipeline therapeutics for Mixed Dyslipidemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Mixed Dyslipidemia therapeutics and enlists all their major and minor projects
- The report assesses Mixed Dyslipidemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Mixed Dyslipidemia


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Mixed Dyslipidemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mixed Dyslipidemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Mixed Dyslipidemia Overview 6
Therapeutics Development 7
Pipeline Products for Mixed Dyslipidemia - Overview 7
Mixed Dyslipidemia - Therapeutics under Development by Companies 8
Mixed Dyslipidemia - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Mixed Dyslipidemia - Products under Development by Companies 12
Mixed Dyslipidemia - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
CymaBay Therapeutics, Inc. 14
Hanmi Pharmaceuticals, Co. Ltd. 15
Matinas BioPharma Holdings, Inc. 16
Pfizer Inc. 17
Thetis Pharmaceuticals LLC 18
Mixed Dyslipidemia - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
bococizumab - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
evolocumab - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
HCP-1105 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
IONIS-ANGPTL3LRx - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
MAT-9001 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
MBX-8025 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TP-452 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Mixed Dyslipidemia - Recent Pipeline Updates 39
Mixed Dyslipidemia - Dormant Projects 55
Mixed Dyslipidemia - Discontinued Products 56
Mixed Dyslipidemia - Product Development Milestones 57
Featured News & Press Releases 57
May 24, 2016: New study results show cholesterol-lowering medication, Repatha (evolocumab), lowers LDL-C when self-administered in at-home setting 57
Apr 01, 2016: Pfizer Announces Positive Topline Results From Second Phase 3 Lipid-Lowering Study Evaluating Bococizumab 58
Mar 16, 2016: Amgen Wins Patent Case On Repatha (Evolocumab) 58
Nov 18, 2015: NICE issues draft guidance on evolocumab for lipid disorder 59
Mar 30, 2014: Data From Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medication Evolocumab Significantly Reduced LDL Cholesterol In Statin Intolerant Patients And In Patients On Statins 60
Mar 29, 2014: New Detailed Data from Three Phase 3 Pivotal Studies Show Amgen's Novel Investigational Cholesterol-Lowering Medicine Evolocumab Significantly Reduced LDL Cholesterol By 55-66 Percent Compared To Placebo In Patients With High Cholesterol 63
Dec 19, 2013: Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab In Patients With High Cholesterol 65
Appendix 68
Methodology 68
Coverage 68
Secondary Research 68
Primary Research 68
Expert Panel Validation 68
Contact Us 68
Disclaimer 69

List of Tables

Number of Products under Development for Mixed Dyslipidemia, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Mixed Dyslipidemia - Pipeline by Amgen Inc., H1 2016 13
Mixed Dyslipidemia - Pipeline by CymaBay Therapeutics, Inc., H1 2016 14
Mixed Dyslipidemia - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 15
Mixed Dyslipidemia - Pipeline by Matinas BioPharma Holdings, Inc. , H1 2016 16
Mixed Dyslipidemia - Pipeline by Pfizer Inc., H1 2016 17
Mixed Dyslipidemia - Pipeline by Thetis Pharmaceuticals LLC, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Mixed Dyslipidemia Therapeutics - Recent Pipeline Updates, H1 2016 39
Mixed Dyslipidemia - Dormant Projects, H1 2016 55
Mixed Dyslipidemia - Discontinued Products, H1 2016 56